NEXT GENERATION

Synlait Milk Limited Interim Results FY18
This presentation is intended to constitute a summary of certain information about Synlait Milk Limited ("Synlait"). It should be read in conjunction with, and subject to, the explanations and views in the documents previously released to the market by Synlait, including Synlait’s Interim Report for the period ended 31 January 2018.

This presentation is provided for information purposes only. The information contained in this presentation is not intended to be relied upon as advice to investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should assess their own individual financial circumstances and should consult with their own legal, tax, business and/or financial advisers or consultants before making any investment decision.

Certain statements in this presentation constitute forward looking statements and projections as they relate to matters other than statements of historical fact. Such forward looking statements and projections are provided as a general guide only based on management’s current expectations and assumptions and should not be relied upon as an indication or guarantee of future performance. Forward looking statements and projections involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Synlait and which are subject to change without notice. Actual results, performance or achievements may differ materially from those expressed or implied in this presentation. No person is under any obligation to update this presentation at any time after its release except as required by law and the NZX Main Board Listing Rules.

Past performance information is given for illustration purposes only and is not indicative of future performance and no guarantee of future returns is implied or given.

While all reasonable care has been taken in relation to the preparation of this presentation, to the maximum extent permitted by law, no representation or warranty, expressed or implied, is made as to the accuracy, adequacy, reliability, completeness or reasonableness of any statements, estimates or opinions or other information contained in this presentation, any of which may change without notice. To the maximum extent permitted by law, Synlait, its subsidiaries, and their respective directors, officers, employees, contractors, agents, advisors and affiliates disclaim and will have no liability and responsibility (including, without limitation, liability for negligence) for any direct or indirect loss or damage which may be suffered by any person through use of or reliance on anything contained in, or omitted from, this presentation.

Forward looking statements in this presentation are unaudited and may include non-GAAP financial measures and information. Not all of the financial information (including any non-GAAP information) will have been prepared in accordance with, nor is it intended to comply with: (i) the financial or other reporting requirements of any regulatory body; or (ii) the accounting principles generally accepted in New Zealand or any other jurisdiction with IFRS. Some figures may be rounded and so actual calculation of the figures may differ from the figures in this presentation. Some of the information in this presentation is based on non-GAAP financial information, which does not have a standardised meaning prescribed by GAAP and therefore may not be comparable to similar financial information presented by other entities. Non-GAAP financial information in this presentation has not been audited or reviewed.

All values are expressed in New Zealand currency unless otherwise stated.

All intellectual property, proprietary and other rights and interests in this presentation are owned by Synlait.

This presentation is not an offer or an invitation to acquire Synlait’s shares or any other financial products and is not a product disclosure statement, prospectus or other offering document, under New Zealand law or any other law.
STRATEGIC UPDATE

John Penno
MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

..........................
OPENING REMARKS

- **RECORD HALF YEAR NET PROFIT OF $40.7 MILLION** COMPARED TO $10.6 MILLION FOR THE SAME PERIOD LAST YEAR (H1 FY17) GENERATED FROM INCREASING CANNED INFANT FORMULA VOLUMES, AND IMPROVED INGREDIENTS MARGINS

- **STRENGTHENED BALANCE SHEET** WITH REDUCTION OF NET DEBT TO $50 MILLION FROM $147 MILLION

- **ACHIEVED ORGANIC GROWTH** IN INFANT FORMULA CAPACITY, WITH VOLUMES UP 36% OVER H2 FY17

- **GEOGRAPHIC GROWTH** INITIATED WITH COMMISSIONING OF SYNLAIT AUCKLAND AND PURCHASE OF SYNLAIT POKENO

- **ANNOUNCED FOODSTUFFS SOUTH ISLAND CONTRACT TO MANUFACTURE FRESH MILK AND CREAM WITH A $125 MILLION INVESTMENT IN ADVANCED LIQUID DAIRY PACKAGING FACILITY TO EXPAND INTO NEW CATEGORIES**

- **ENHANCED CAPABILITY** WITHIN SENIOR LEADERSHIP TEAM WITH THREE NEW APPOINTMENTS

- **INVESTMENT IN RESEARCH AND DEVELOPMENT** WITH THE OPENING OF SYNLAIT PALMERSTON NORTH

- **UNLOCKING CAPACITY** WITH THE COMMISSIONING OF THE NEW WETMIX KITCHEN AT SYNLAIT DUNSANDEL

- **ACHIEVED CFDA REGISTRATION** FOR THE a2 MILK COMPANY’S™ INFANT FORMULA IN CHINA
WE ARE A GROWTH COMPANY
TO SUCCEED

WE WILL LEVERAGE OUR UNIQUE VALUE CHAIN IN EACH CATEGORY TO BUILD SUCCESSFUL BUSINESSES THAT CONTRIBUTE TO OUR LONG-TERM SUCCESS
OUR CATEGORIES

DELIVERED IN CONSUMER, FOODSERVICE AND INGREDIENTS PACKAGING

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Infant Nutrition</th>
<th>Everyday Dairy</th>
<th>Adult Nutrition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Build Sales - People, Technical</td>
<td>Blending + Consumer Packaging II</td>
<td>Fresh Milk</td>
<td>Product Development</td>
</tr>
<tr>
<td>Tailor Product to Customer Need</td>
<td>Wetmix II</td>
<td>Export Cream Opportunities</td>
<td>Market Research</td>
</tr>
<tr>
<td>RTD Infant Formula</td>
<td></td>
<td></td>
<td>RTD Blended Dairy Beverage</td>
</tr>
</tbody>
</table>

DELIVERED IN CONSUMER, FOODSERVICE AND INGREDIENTS PACKAGING

<table>
<thead>
<tr>
<th>Diversify Markets - Categories, Customers, Geography</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Contributor to Strategic Goal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deliver Higher Value Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Contributor to Strategic Goal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Adapt to a Changing World Demographic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Contributor to Strategic Goal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Focus on B2B, but Move Closer to Customers and Consumers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Contributor to Strategic Goal</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Build Supply Chain Integrity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong Contributor to Strategic Goal</td>
</tr>
</tbody>
</table>
A PORTFOLIO OF INFANT FORMULA CUSTOMER PARTNERSHIPS

- STAGE 4 INFANT FORMULA MANUFACTURED SINCE JUNE 2017
- CHINESE FOOD AND DRUG ADMINISTRATION (CFDA) REGISTRATION RECEIVED IN FY17
- EXCLUSIVE SUPPLIER OF THE A2 MILK COMPANY’S INFANT FORMULA TO CHINA AND AUSTRALASIA MARKETS

- CURRENTLY AVAILABLE IN AUSTRALIA AND NEW ZEALAND
- DISTRIBUTING NATIONWIDE IN AUSTRALIA THROUGH COLES SUPERMARKETS
- PENDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) REVIEW

- NEW FIVE-YEAR SUPPLY AGREEMENT SIGNED IN AUGUST 2017
- CFDA REGISTRATION APPLICATION SUBMITTED

- NEW SUPPLY AGREEMENT SIGNED IN FEBRUARY 2018
- CFDA APPLICATION TO BE SUBMITTED APRIL 2018
WE HAVE UNLOCKED INFANT FORMULA CAPABILITY

CONTRACTED FARMS
- APPROX 200
  - 62 a2 MILK™ FARMS
  - 20 GRASS FED™ FARMS
  - 25 LEAD WITH PRIDE™ FARMS
  - 91 REGULAR FARMS

MILK SOLIDS
- 65.0 kgMS (FY17)
  - 19.8 m
  - 6.9 m
  - 8.8 m
  - 27.6 m
  - 1.7 m Other Suppliers

WETMIX KITCHENS
- 80,000 MT
- MAX. CAPACITY
  - WETMIX ONE
    - 40,000 MT
  - WETMIX TWO
    - 40,000 MT (Commissioned Nov 17)

THREE HIGH SPECIFICATION SPRAY DRYERS
- 120,000 MT
- MAX. CAPACITY
  - D3 (INFANT FORMULA CAPABLE)
    - 40,000 MT
  - D2 (INFANT FORMULA CAPABLE)
    - 40,000 MT
  - D1 (INFANT-GRADE WMP + SMP)
    - 40,000 MT
  - 20,000 MT
    - AMF™ PLANT

CONSUMER PACKAGING
- 93,000 MT TOTAL CAPACITY
  - 35,000 MT (CANNING)
    - DUNSANDEL
  - 35,000 MT (CANNING)
    - AUCKLAND
      - (Commissioned Nov 17)
  - 23,000 MT
    - SACHET LINES PLANNED

Wetmix Two enables both of our large-scale infant formula spray dryers to simultaneously manufacture infant formula base powder.

Synlait Auckland’s new blending and canning line doubles our canned infant formula capacity.

*Some Lead With Pride™ farms also supply a2 MILK™ and Grass Fed™, total Lead With Pride™ farms is 53.

Note: AMF = Anhydrous Milk Fat
- Synlait is investing in nutritional powder manufacturing capacity to meet customer demand for infant formula products

- Establishing this capacity on a second site allows mitigation of our current single-site risk

- Also introduces access to a second milk pool which further reduces our risk profile

- Our site acquired in Pokeno, North Island meets these needs while also providing a platform for growth in other categories

- Initial investment on site will be one infant formula capable spray dryer and related infrastructure at a cost of circa $260 million, capable of manufacturing 40,000 MT of infant base powder per annum

- Investment to be funded through debt facilities
TRANSFORMATIONAL IN THE DAIRY INDUSTRY, SYNLAIT’S LEAD WITH PRIDE™ PROGRAMME RECOGNISES AND REWARDS THOSE SUPPLIERS WHO ARE ACHIEVING DAIRY FARMING EXCELLENCE. LEAD WITH PRIDE™ IS AUSTRALASIA’S ONLY INTERNATIONALLY ACCREDITED ISO / IEC 17065 DAIRY FARM ASSURANCE SYSTEM AND MEASURES DAIRY FARMS ON FOUR PILLARS OF DAIRY FARMING; ENVIRONMENT, ANIMAL HEALTH AND WELFARE, MILK QUALITY, AND SOCIAL RESPONSIBILITY.
ENTRY INTO EVERYDAY DAIRY WITH LIQUID MILK

- Exclusive supply arrangement with Foodstuffs South Island to supply private label fresh milk and cream (Value and Pams brands) from early 2019

- Distributed in their network of PAK’n SAVE, New World, Four Square and On The Spot stores

- Ten year agreement with demand to underpin capital investment

- $125 million modern and sophisticated advanced liquid dairy packaging facility to be constructed at our Dunsandel site

- Investment to be funded through debt facilities

- Annual capacity of 110 million litres of which one third will be initially utilised for Foodstuffs South Island products

- Synlait’s current milk supply adequate to meet the volumes of the contract

- New facility will be capable of manufacturing a range of traditional and new products

- New product development to be supported from our new R+D centre in Palmerston North

- Long life cream export category also presents attractive opportunities we intend to pursue
MASSEY AND FOODPILOT CORE TO DELIVERING SYNLAIT’S ASPIRATIONS

- Synlait Palmerston North was opened on Friday 2 March by Massey University’s Vice Chancellor, Professor Jan Thomas, and the mayor of Palmerston North, Grant Smith

- Our Palmerston North R+D capability consists of a laboratory, office and access to Massey University’s FoodPilot plant

- FoodPilot is the largest and best equipped publically accessible pilot plant in the Southern Hemisphere

- Massey University offers access to an extensive network of expertise

- Extensive lab facilities covering multiple disciplines

- Palmerston North is the hub of dairy R+D in New Zealand (surrounded by Crown Research Institutes like Ag Research, Plant and Food)

- While Palmerston North will initially focus on dairy liquids, we have R+D teams elsewhere working on nutritional powders, packaging and many other areas
Deborah Marris - General Counsel and Head of Commercial

Deborah Marris is joining Synlait from her previous role as Managing Director, Global Compliance with Barclays Bank, India.

Prior to that she held senior executive roles with other global organisations, including as General Counsel (Asia Pacific, Europe and America), Chief of Staff (New Zealand) and also Head of Tax (New Zealand) for ANZ Bank.

Deborah established her career initially with 15 years working as a senior lawyer for firms throughout New Zealand, the United Kingdom and Hong Kong.

Deborah holds a Bachelor of Commerce and Administration and a Bachelor of Laws (Honors) from Victoria University of Wellington and is a qualified barrister and solicitor in New Zealand.

Dr. Suzan Horst - Director of Quality, Regulatory and Laboratory Services

Suzan Horst has most recently been Director Quality Affairs, Business Group EMEA (Europe, the Middle East and Africa) for FrieslandCampina. She has held other senior roles since joining them in 2005, including Director Corporate QA, crisis and issue management and Corporate Quality Assurance Manager.

Prior to joining FrieslandCampina, Suzan was Global Food Safety Competence Manager for Nutreco B V and lectured agricultural economics and food safety before that.

Suzan holds a Ph.D. in Agricultural Economics and a Bachelor of Science in Animal Husbandry from the Wageningen University and Research Centre in the Netherlands, part of which involved study at Massey University in New Zealand.

Hamish Reid - General Manager of Brand and Chief Sustainability Officer

Hamish Reid takes the lead on developing Synlait’s strategy for sustainability with a particular focus on our aspiration to further improve our environmental and social performance from farm to fridge. He will also lead our thinking as we continue evaluating potential B2C opportunities.

Hamish has deep experience in food and beverage marketing, predominantly for Danone in Paris and Saatchi & Saatchi in London. More recently, Hamish has established an award-winning not-for-profit in New Zealand and consulted to businesses around the world developing environmental and social programmes that boost economic performance.
OUR FINANCIAL RESULTS

Nigel Greenwood
CHIEF FINANCIAL OFFICER

..........................
OVERVIEW

- First half profit eclipses all previous results
- Profit growth is product margin led, driven by increasing canned infant formula volumes, and improved ingredients margins
- First half performance includes some gains not expected to be repeated in the second half
- Lower debt levels have continued to improve profit and loss leverage

EBIT INCREASED TO $61.2m (H1 FY17: $21.9m)
NET DEBT DECREASED FROM $147m TO $50m
- H1 FY18 powders and cream volumes down on prior year due to:
  - Increase of milk consumed in canned infant formula
  - Sell down of distressed inventory in H1 FY17
- Despite lower sales volume, the proportion of powders and cream sold in the first half relative to full year expectations was 48% (H1 FY17 45%)
- Growth trajectory of canned infant formula has continued, with total consumer packaged volumes nearly tripling from the same period last year and up 36% on H2 FY17
- Finished goods inventory of 35,040 MT was 18% lower than H1 FY17, reflecting improved inventory management and supporting growth in operating cash flow

*Sales volumes for specialty ingredients are not shown on the graph.*
First half contracted milk supply consistent with prior years’ collections at 41.4 million kgMS

- Total production volumes slightly down on H1 FY17 (81,815 MT vs 82,980 MT)

- Increased infant base powder production to meet canned infant formula demand has seen 3.3 million kgMS sold (0.4 million kgMS H1 FY17)

- Milk production exhibits seasonality that drives overhead recovery, with 61% of expected FY18 milk processed in H1
Consumer packaged sales volume growth and improved ingredient margins have driven the increase in gross profit per MT from $830 per MT to $1,390 per MT.

Margin expansion has been:
- Reduced sales of powders and cream products (18.8%) following the uncommon sell down in H1 FY17
- High utilisation of all facilities, particularly Wetmix and consumer packaging
- Intra-seasonal timing differences that are not forecast to repeat in the second half
- Reduction of onerous contracts provision from $6.2 million in H1 FY17 to $0.2 million in H1 FY18

All of these have supported a $41.5 million increase in Gross Profit to $85.2 million.

Management expect some of this margin expansion to retrace in the second half due to:
- Spare capacity following commissioning of our new Wetmix and consumer packaging facilities
- Seasonal variation in milk production
- Sales phasing upside not expected to be repeated in H2 FY18
- Net overheads have increased by 13.1% over H1 FY17 to $24.5 million, however only $1.4 million, or 6%, above H2 FY17

- Largest driver of the increase is employee costs, which reflects the continued investment into capability for research and development, business development and leadership to support continuing growth and diversification
- Synlait generated strong operating cash flows in H1 FY18 of $75.0 million. This is an improvement of $89.2 million from the same period last year and pleasing in the part of the year that typically experiences weak cash flows.

- The improvement in operating cash flow has been driven by:
  - Better sales deliveries resulting in lower inventory on hand, generating $33.6 million.
  - Increased sales to customers in our receivables assignment program increasing from $38.5 million to $70.5 million.
  - Returning to more traditional advance rate profiles for contracted milk suppliers from abnormally high rates in H1 FY17, generating a further $21.9 million of operating cash flow.
  - Increased infant formula sales leading to increased customer deposits of $13.8 million.

### Year-on-Year Operating Cash Flow

<table>
<thead>
<tr>
<th></th>
<th>H1 FY16</th>
<th>H2 FY16</th>
<th>H1 FY17</th>
<th>H2 FY17</th>
<th>H1 FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventory Reduction</td>
<td>4.0</td>
<td></td>
<td></td>
<td></td>
<td>(14.2)</td>
</tr>
<tr>
<td>Receivables Assigned</td>
<td>100.4</td>
<td></td>
<td>129.3</td>
<td></td>
<td>75.0</td>
</tr>
<tr>
<td>Milk Payments</td>
<td></td>
<td>21.9</td>
<td></td>
<td>13.8</td>
<td>(12.1)</td>
</tr>
<tr>
<td>Customer Deposits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>100.4</td>
<td>21.9</td>
<td>129.3</td>
<td>13.8</td>
<td>75.0</td>
</tr>
</tbody>
</table>

![Operating Cash Flow Diagram](image)
- Record operating cash flow generation of $204.3 million for the 12 months ended 31 January 2018 has fully funded our capital expenditure program and enabled the reduction of debt to low levels.

- In the 12 months to 31 January 2018, Synlait has invested $89.6 million in capital expenditure. The major components of this were Synlait Auckland ($49.1 million) and our new Wetmix kitchen ($29.2 million).

- This leaves the company well placed to fund its expansion plans in Dunsandel (advanced liquid dairy packaging facility $125 million) and Pokeno ($260 million infant formula manufacturing facility).

1 Based on a rolling 12 month EBITDA (trailing)
- The material increase in first half earnings has been achieved from both large increases in manufacture and sales of our highest margin products, and through improved margin, and earlier sales of our ingredients products.

- This earlier phasing of ingredients, combined with increasing commitments to R+D and business development, means earnings in the second half are expected to be lower than the first half.

- Although the second half of FY18 is not expected to be as strong as the first half, we continue to forecast strong overall earnings growth for the full year.

- Looking forward into FY19, ongoing growth in infant formula volumes are expected to continue to grow earnings.
APPENDIX
GROSS PROFIT PER MT (POWDERS AND CREAM)

POWDERS AND CREAM GROSS PROFIT PER MT

- H1 FY16: $837
- H2 FY16: $726
- H1 FY17: $667
- H2 FY17: $692
- H1 FY18: $1,115
GROSS PROFIT PER MT (CONSUMER PACKAGED)
- Synlait has a strong and growing customer base for lactoferrin, spanning from use in health supplements to infant formula.

- A demand and supply imbalance is driving a global strengthening in lactoferrin prices.

- Demand for lactoferrin is driven by increasing use in infant formula, particularly in China.

- Synlait is well placed to deliver to global demand, with significant expertise in lactoferrin production.

- In FY17, Synlait also gained FDA approval to export lactoferrin to the U.S. market for use in infant formula, enabling further market opportunities.
INVESTORS
Casey Blatch, Strategic Finance Manager
+64 3 373 3091
Casey.Blatch@synlait.com

MEDIA
Dan Walraven, Communications Manager
+64 27 836 7532
Daniel.Walraven@synlait.com